<DOC>
	<DOCNO>NCT00820014</DOCNO>
	<brief_summary>The purpose study determine whether ESBA105 , single-chain ( scFv ) antibody TNF-alpha , efficiently penetrate anterior chamber vitreous body upon topical administration eye .</brief_summary>
	<brief_title>Ocular Biodistribution Study Topically Applied ESBA105</brief_title>
	<detailed_description>ESBA105 topically administer tumour necrosis factor alpha ( TNF-alpha ) inhibitor significant therapeutic potential various inflammatory intraocular disease . In animal experiment , ESBA105 show efficiently penetrate inner eye upon topical administration , associate low systemic exposure . A recently complete Phase I trial topical ESBA105 confirm safety topical administration human eye low systemic exposure use route administration . This study design determine intraocular level specific intraocular distribution pattern ESBA105 follow topical administration human eye . In addition shall explore whether topical administration ESBA105 reduce intraocular inflammation follow cataract surgery . Three different dose regimen apply four different patient cohort . Three patient cohort conduct open label design one double-masked , placebo control design .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<criteria>Male female Caucasian patient â‰¥18 year . Written inform consent prior study procedure include screen test eligibility . Patients good health determine past medical history , physical examination , vital sign , electrocardiogram ( ECG ) , laboratory test screen . Ability administer eye drop ( personally administer another person ) . Cataract patient : Eligible routine , uncomplicated senile cataract surgery . Vitrectomy patient : Diagnosis epiretinal fibroplasia require vitrectomy cataract surgery . Treated glaucoma / elevate intraocular pressure ( IOP ) require therapy . History chronic recurrent intraocular inflammatory disease . Uncontrolled diabetes mellitus ( fast blood glucose &gt; 15 mmol/L ) . Diabetic retinopathy history laser photocoagulation . Patients single eye pinholed visual acuity ( VA ) 20/200 bad measure Snellen chart nonstudy eye . Iris atrophy eye undergo surgery . Pregnant breastfeed woman woman childbearing potential , partner refuse use 2 reliable method contraception History collagenosis systemic vasculitis . Patients ocular surgery ( include laser surgery ) study eye within 3 month contralateral eye within 2 week prior screen . Patients active systemic local ( anywhere body ) bacterial and/or viral infection . Positive unclear QuantiFERONTB Gold assay result . Participation clinical study investigational drug within 3 month prior screen . Inability comply study requirement . Patients know , severely impaired hepatic function , laboratory value reflect inadequate hepatic function . Patients preexist chronic renal failure define calculated creatinine clearance ( CrCl ) &lt; 40 mL/min , use CockcroftGault estimate glomerular filtration rate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>ESBA105</keyword>
	<keyword>scFv antibody fragment</keyword>
	<keyword>cataract surgery</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>biodistribution</keyword>
	<keyword>Irvine-Gass syndrome</keyword>
</DOC>